ORGANOGENESIS HOLDINGS INC
ORGONASDAQTrading Snapshot
- Day Range
- $267.05 – $273.20
- 52-Week Range
- $1.34 – $7.08
- Volume
- $1.58B
- Avg Volume
- $1.90B
- Shares Outstanding
- 128.7M
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $563M
- Last Q Revenue
- $44M
- P/E Ratio
- -1.7
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-0.70
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
Why Investors Own ORGO
- ✓High-growth profile — revenue up +8.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ORGANOGENESIS HOLDINGS INC
ORGO
StockOtter · stockotter.spaceAbout ORGANOGENESIS HOLDINGS INC
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ORGANOGENESIS HOLDINGS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ORGO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ORGANOGENESIS HOLDINGS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.